Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Doxorubicin + Sargramostim + STEMVAC |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 13 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
| STEMVAC | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine | STEMVAC is a cancer vaccine that encodes multiple class II epitopes that result in a Th1 response upon expression, potentially leading to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10, NCI Drug Dictionary). | ||
| Sargramostim | Leukine | GM-CSF|Prokine |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07078604 | Phase II | Docetaxel + Sargramostim + STEMVAC Paclitaxel + Sargramostim + STEMVAC Carboplatin + Sargramostim + STEMVAC Doxorubicin + Sargramostim + STEMVAC Cisplatin + Sargramostim + STEMVAC Eribulin + Sargramostim + STEMVAC Pegylated liposomal doxorubicin + Sargramostim + STEMVAC | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | Not yet recruiting | USA | 0 |